Cyclin-Dependent Kinase (CDK) 9 Inhibitor

Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors.

Voruciclib, a selective orally administered, inhibitor of CDK9, is in clinical development for acute myeloid leukemia. Applications in solid tumors are also being evaluated in non-clinical models.

CDK9 has important functions in cell cycle regulation, including the modulation of two therapeutic targets in cancer: myeloid leukemia cell differentiation protein ("MCL1") and the MYC proto-oncogene protein ("MYC") which regulates cell proliferation and growth. Voruciclib is currently being evaluated in a Phase 1 trial evaluating dose and schedule in patients with relapsed or refractory (R/R) acute myeloid leukemia ("AML"). Applications in solid tumors are also being considered where MYC is dysregulated.

Additional Information

Mechanism of Action
Development Program
Patient Population
Clinical Trials

Clinical Trials

MEI is actively recruiting patients to participate in clinical trials to evaluate our investigational cancer therapies.
View All
Patients & Caregivers

Patients & Caregivers

Our driving purpose and principle is simple: deliver novel and differentiated cancer therapies that provide improved outcomes for patients.
Learn More